AFT Pharmaceuticals sees multi-billion-dollar R&D opportunity after latest FDA milestone
Key Takeaways
- •AFT Pharmaceuticals said it has received tentative FDA approval for a new patented medicine, marking its third product to clear the U.S. approval process.
- •Chief executive Hartley Atkinson said the company now has eight patented products in its portfolio.
- •Atkinson said AFT has several research and development projects underway.
- •He pointed to Maxigesic Rapid Tablets and Maxigesic IV as earlier examples of the company converting ideas into regulated market entries.
HotCopper’s latest Watchlist featured AFT Pharmaceuticals (ASX:AFP) founder and chief executive Hartley Atkinson, who discussed the company’s expanding global reach and the “tentative” FDA approval it has just received, marking the third patented medicine to clear that key U.S. hurdle.
Listen to the HotCopper podcast for in-depth discussions and insights on the biggest headlines from throughout the week on Spotify, Apple, and more.
Atkinson said the latest FDA milestone supports what he described as “a really good portfolio” for the Australian pharmaceutical distributor.
“We now have eight patented products, some are always arguably going to be bigger than others… but, there’s so many interesting projects,” he said in the interview. “We have some really good R&D projects underway.”
He said the sequence matters because it shows the company has already taken more than one product from idea to regulated market entry, with the latest approval adding another distinct program to the mix. For a pharma business, that kind of repeatability can be as important as a single headline milestone, since development progress often depends on proving a platform can work across multiple candidates rather than one-off successes.
“We have a good indication now that we can succeed. The first two projects were Maxigesic Rapid Tablets and then Maxigesic IV, and now we’ve added a completely different product on as well, so I think people can see that we can convert our ideas and products into something that’s actually tangible.”
The full AFP Watchlist interview can be watched in the browser above.
Join the discussion: see what HotCopper users are saying about AFT Pharmaceuticals Ltd and take part in the conversations moving the markets.
Disclaimer: This article is disseminated in partnership with AFT Pharma Ltd. It is intended to inform investors and should not be taken as financial advice.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.